Stock AMRN AMARIN CORPORATION PLC
Add to a list
To use this feature you must be a member
Log inSign up

Amarin Corporation plc Stock

Equities

AMRN

US0231112063

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-19 pm EDT 		5-day change 1st Jan Change
0.8593 USD -1.43% Intraday chart for Amarin Corporation plc -10.21% -1.23%
Apr. 19 European Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading But End Week Down MT
Apr. 18 European Equities Traded in the US as American Depositary Receipts Flat in Thursday Trading MT

Financials (USD)

Sales 2024 * 224M Sales 2025 * 231M Capitalization 353M
Net income 2024 * -60M Net income 2025 * -52M EV / Sales 2024 * 0.6 x
Net cash position 2024 * 217M Net cash position 2025 * 187M EV / Sales 2025 * 0.72 x
P/E ratio 2024 *
-5.77 x
P/E ratio 2025 *
-6.42 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 92.73%
More Fundamentals * Assessed data

Chart Amarin Corporation plc

Dynamic Chart

Latest news about Amarin Corporation plc

European Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading But End Week Down MT
European Equities Traded in the US as American Depositary Receipts Flat in Thursday Trading MT
European Equities Traded in the US as American Depositary Receipts Trend Lower in Wednesday Trading MT
European Equities Traded in the US as American Depositary Receipts Lower in Friday Trading MT
European Equities Traded in the US as American Depositary Receipts Trend Lower in Wednesday Trading MT
European Equities Traded in the US as American Depositary Receipts Trend Lower in Tuesday Trading MT
Amarin Corporation plc Announces New Reduce-It® Analyses Show Vascepa®/Vazkepa® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups CI
European Equities Traded in the US as American Depositary Receipts Higher in Friday Trading, Close Out Week Lower MT
European Equities Traded in the US as American Depositary Receipts Trend Higher in Thursday Trading MT
European Equities Traded in the US as American Depositary Receipts Trend Higher in Wednesday Trading MT
European Equities Traded in the US as American Depositary Receipts Fall in Tuesday Trading MT
European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Tuesday Trading MT
European Equities Traded in the US as American Depositary Receipts Ease Wednesday MT
European Equities Traded in the US as American Depositary Receipts Start Week Slightly Lower in Monday Trading MT
European Equities Traded in the US as American Depositary Receipts Trend Higher in Tuesday Trading MT
More news

Latest transcript on Amarin Corporation plc

Logo Amarin Corporation plc
Amarin Corporation plc, Q4 2023 Earnings Call, Feb 29, 2024
More transcripts

Analyst Recommendations on Amarin Corporation plc

Jefferies Downgrades Amarin to Hold From Buy, Cuts Price Target to $1 From $3 MT
Northland Adjusts Price Target on Amarin to $1.25 From $2, Maintains Market Perform Rating MT
Jefferies Upgrades Amarin to Buy From Hold, Adjusts Price Target to $3 From $1.30 MT
European Equities Follow US Markets Lower on Interest Rate Concerns MT
SVB Securities Adjusts Amarin's Price Target to $2 From $3, Maintains Market Perform Rating MT
More recommendations

Press releases Amarin Corporation plc

Amarin to Report First Quarter 2024 Financial Results and Host Conference Call on May 1, 2024 GL
Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ACC.24 GL
New REDUCE-IT® Analyses Show VASCEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups AQ
New REDUCE-IT® Analyses Show VASCEPA®/VAZKEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups AQ
New REDUCE-IT® Analyses Show VASCEPA®/VAZKEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups GL
More press releases

News in other languages on Amarin Corporation plc

Amarin reçoit un remboursement pour VAZKEPA® en Suède
Amarin recibe reembolso por VAZKEPA® en Suecia
Amarin erhält Kostenerstattung für VAZKEPA® in Schweden
Une récente analyse démontre que VASCEPA® (icosapent éthyl) a considérablement réduit le risque d'événements cardiovasculaires potentiellement mortels chez des patients ayant déjà subi une intervention coronaire percutanée
Jüngste Analysen zeigen, dass VASCEPA® (Icosapent-Ethyl) das Risiko potenziell tödlicher kardiovaskulärer Ereignisse bei Patienten mit vorheriger perkutaner Koronarintervention signifikant gesenkt hat
More news

Quotes and Performance

1 day-1.43%
1 week-10.21%
Current month-3.54%
1 month-0.95%
3 months-18.16%
6 months+16.52%
Current year-1.23%
More quotes

Highs and lows

1 week
0.86
Extreme 0.8593
0.99
1 month
0.83
Extreme 0.8339
1.11
Current year
0.80
Extreme 0.8015
1.37
1 year
0.65
Extreme 0.651
1.49
3 years
0.65
Extreme 0.651
5.97
5 years
0.65
Extreme 0.651
26.12
10 years
0.65
Extreme 0.651
26.12
More quotes

Managers and Directors - Amarin Corporation plc

Managers TitleAgeSince
Patrick Holt CEO
 Chief Executive Officer 52 23-07-17
Thomas Reilly DFI
 Director of Finance/CFO 52 22-06-19
Jonathan Provoost CMP
 Compliance Officer 55 Nov. 14
Members of the board TitleAgeSince
Louis Sterling BRD
 Director/Board Member 45 23-02-27
Odysseas Kostas CHM
 Chairman 49 23-02-27
Keith Horn BRD
 Director/Board Member 66 23-02-27
More insiders

Quotes

Date Price Change Volume
24-04-19 0.8593 -1.43% 1,024,688
24-04-18 0.8718 -4.94% 1,038,043
24-04-17 0.9171 +2.37% 881,689
24-04-16 0.8959 -2.47% 812,512
24-04-15 0.9186 -4.01% 626,156

Delayed Quote Nasdaq, April 19, 2024 at 04:00 pm EDT

More quotes

Company Profile

Amarin Corporation PLC is a pharmaceutical company. The Company is focused on the commercialization and development of therapeutics to improve cardiovascular (CV), health and reduce CV risk. The Company operates through the development and commercialization of VASCEPA. Its lead product, Vascepa (icosapent ethyl) capsule is used as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. This indication for Vascepa, known as the MARINE indication, is based primarily on the results from the MARINE study of Vascepa in this approved patient population. The Company sells Vascepa principally to wholesalers, as well as selected regional wholesalers and specialty pharmacy providers, or collectively, its distributors, which in turn resell Vascepa to retail pharmacies for resale to patients and healthcare providers.
Sector
Biotechnology & Medical Research
Calendar
2024-05-01 - Q1 2024 Earnings Release
More about the company

Income Statement Evolution

More financial data

Ratings for Amarin Corporation plc

Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
UNDERPERFORM
Number of Analysts
4
Last Close Price
0.8718 USD
Average target price
1.083 USD
Spread / Average Target
+24.26%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
AMARIN CORPORATION PLC Stock Amarin Corporation plc
-1.23% 358M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-3.10% 102B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+2.11% 96.07B
ARGENX SE Stock argenx SE
-1.80% 21.66B
BIONTECH SE Stock BioNTech SE
-17.75% 20.77B
GENMAB A/S Stock Genmab A/S
-6.91% 18.53B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-42.00% 16.91B
BEIGENE, LTD. Stock BeiGene, Ltd.
-28.19% 13.79B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+0.18% 13.33B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+19.90% 10.94B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. AMRN Stock